Disclosures
Dr Raal received consulting fees and honoraria from Amgen, Novartis Pharmaceuticals, Regeneron Pharmaceuticals, and LIB Therapeutics. Dr Durst received consulting fees and honoraria from Novartis and Sanofi, lecturing fees from Novartis, and honoraria from Medison. Drs Bi, Talloczy, Maheux, and Lesogor are full-time employees of Novartis and have Novartis stocks or stock options. Dr Kastelein received consulting fees from 89Bio, Esperion Therapeutics, Madrigal, CiVi Therapeutics, North Sea Therapeutics, CSL-Behring, Novartis, Inversago, Draupnir, CinCor, and Scribe Therapeutics; is a board member of North Sea and Staten Biotech; is Chief Scientific Officer of New Amsterdam Pharma; is acting Chief Medical Officer of Staten Biotech; and holds stock and stock options in New Amsterdam.